Literature DB >> 24976077

Identification of microRNAs differentially expressed in prostatic secretions of patients with prostate cancer.

Esra Guzel1, Omer F Karatas, Atilla Semercioz, Sinan Ekici, Serdar Aykan, Serhat Yentur, Chad J Creighton, Michael Ittmann, Mustafa Ozen.   

Abstract

Prostate cancer (PCa) is one of the leading causes of cancer deaths in men. Since there are limited treatment options available for the advanced tumors, there is an urgent need for novel diagnostic tools for PCa. Prostate secretion samples (PSS) from 23 PCa and 25 benign prostate hyperplasia (BPH) patients were obtained from Urology Department of Bagcilar Educational and Research Hospital (Istanbul). MicroRNA (miRNA) profiling of eight PSS (four from BPH, four from PCa patients) was performed using microarray. Four of significantly deregulated miRNAs were further confirmed using quantitative reverse-transcription PCR (qRT-PCR). Statistical analysis was performed using Student's t-test. ROC curves were plotted with SPSS-15.0. In this study, we aimed to identify a miRNA expression signature that could be used to distinguish PCa from BPH. MiRNA profiling of four PCa and four BPH patients with microarray revealed that miR-361-3p, miR-133b and miR-221 were significantly downregulated and miR-203 was upregulated in PSS of PCa patients. Further qRT-PCR analysis confirmed the altered expressions of these four miRNAs in PSS of 23 PCa and 25 BPH patients. Four miRNAs, together and individually have much power (AUC; 0.950) than PSA has (AUC; 0.463) to discriminate PCa from BPH patients. We have shown for the first time in the literature the presence of miRNAs in the PSS. We suggest PSS as a powerful non-invasive source for evaluation of prognosis in PCa, since prostate massages can be easily applied during routine examination. Our results showed that certain differentially expressed miRNAs in PSS could be used as diagnostics markers.
© 2014 UICC.

Entities:  

Keywords:  benign prostatic hyperplasia; diagnostic biomarkers; microRNA; prostate cancer

Mesh:

Substances:

Year:  2014        PMID: 24976077     DOI: 10.1002/ijc.29054

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  25 in total

1.  Association between age-related reductions in testosterone and risk of prostate cancer-An analysis of patients' data with prostatic diseases.

Authors:  Kai Wang; Xinguang Chen; Victoria Y Bird; Travis A Gerke; Todd M Manini; Mattia Prosperi
Journal:  Int J Cancer       Date:  2017-07-24       Impact factor: 7.396

2.  Identification of miR-139-5p as a saliva biomarker for tongue squamous cell carcinoma: a pilot study.

Authors:  Mehmet Bugrahan Duz; Omer Faruk Karatas; Esra Guzel; Nesrettin Fatih Turgut; Mehmet Yilmaz; Chad J Creighton; Mustafa Ozen
Journal:  Cell Oncol (Dordr)       Date:  2015-12-09       Impact factor: 6.730

3.  MicroRNA Regulating Glutathione S-Transferase P1 in Prostate Cancer.

Authors:  Savita Singh; Girish C Shukla; Sanjay Gupta
Journal:  Curr Pharmacol Rep       Date:  2015-04-01

4.  Integrated Analysis Reveals together miR-182, miR-200c and miR-221 Can Help in the Diagnosis of Prostate Cancer.

Authors:  Yinmin Gu; Danqing Lei; Xia Qin; Panyu Chen; Yi Ming Zou; Yanling Hu
Journal:  PLoS One       Date:  2015-10-20       Impact factor: 3.240

5.  The utility of urine-circulating miRNAs for detection of prostate cancer.

Authors:  Kristina Stuopelyte; Kristina Daniunaite; Arnas Bakavicius; Juozas R Lazutka; Feliksas Jankevicius; Sonata Jarmalaite
Journal:  Br J Cancer       Date:  2016-08-04       Impact factor: 7.640

6.  Chitosan nanoparticle-mediated delivery of miRNA-34a decreases prostate tumor growth in the bone and its expression induces non-canonical autophagy.

Authors:  Sanchaika Gaur; Yunfei Wen; Jian H Song; Nila U Parikh; Lingegowda S Mangala; Alicia M Blessing; Cristina Ivan; Sherry Y Wu; Andreas Varkaris; Yan Shi; Gabriel Lopez-Berestein; Daniel E Frigo; Anil K Sood; Gary E Gallick
Journal:  Oncotarget       Date:  2015-10-06

Review 7.  Diagnostic, prognostic and predictive value of cell-free miRNAs in prostate cancer: a systematic review.

Authors:  Edgars Endzeliņš; Vita Melne; Zane Kalniņa; Vilnis Lietuvietis; Una Riekstiņa; Alicia Llorente; Aija Linē
Journal:  Mol Cancer       Date:  2016-05-18       Impact factor: 27.401

8.  A circulating miRNA assay as a first-line test for prostate cancer screening.

Authors:  Evgeniya Sharova; Angela Grassi; Anna Marcer; Katia Ruggero; Francesco Pinto; Pierfrancesco Bassi; Paola Zanovello; Filiberto Zattoni; Donna M D'Agostino; Massimo Iafrate; Vincenzo Ciminale
Journal:  Br J Cancer       Date:  2016-05-26       Impact factor: 7.640

9.  Predictive microRNAs for lymph node metastasis in endoscopically resectable submucosal colorectal cancer.

Authors:  Chan Kwon Jung; Seung-Hyun Jung; Seon-Hee Yim; Ji-Han Jung; Hyun Joo Choi; Won-Kyung Kang; Sung-Won Park; Seong-Taek Oh; Jun-Gi Kim; Sug Hyung Lee; Yeun-Jun Chung
Journal:  Oncotarget       Date:  2016-05-31

10.  The expression of microRNA 574-3p as a predictor of postoperative outcome in patients with esophageal squamous cell carcinoma.

Authors:  Tomoyuki Okumura; Hirohumi Kojima; Takeshi Miwa; Shinichi Sekine; Isaya Hashimoto; Shozo Hojo; Takuya Nagata; Yutaka Shimada
Journal:  World J Surg Oncol       Date:  2016-08-26       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.